Seth C Hopkins (Seth Hopkins)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 23

Top Topics

Bipolar Disorder

Top Venues

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

Translational psychiatry

Diabetes, obesity & metabolism

Pharmacology research & perspectives

This page only lists publications with an associated author ORCID identifier.

Publications

Guangqing Xiao, Hironobu Tsukada, Yu-Luan Chen, Lei Shi, Seth C Hopkins, Gerald R Galluppi
Evaluation of OCT2-mediated drug-drug interactions between ulotaront and metformin in subjects with schizophrenia. Pharmacology research & perspectives 12 (2) (2024)
Snežana Milanović, Nina Dedic, Robert Lew, Duane Burton, Kenneth S Koblan, Michael Camilleri, Seth C Hopkins
TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes. Diabetes, obesity & metabolism 26 (6) (2024)
Snežana Milanović, Nina Dedic, Robert Lew, Duane Burton, Kenneth S Koblan, Michael Camilleri, Seth C Hopkins
TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes. Diabetes, obesity & metabolism 26 (6) (2024)
Snežana Milanović, Nina Dedic, Robert Lew, Duane Burton, Kenneth S Koblan, Michael Camilleri, Seth C Hopkins
TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes. Diabetes, obesity & metabolism (2024)
Guangqing Xiao, Hironobu Tsukada, Yu-Luan Chen, Lei Shi, Seth C Hopkins, Gerald R Galluppi
Evaluation of OCT2-mediated drug-drug interactions between ulotaront and metformin in subjects with schizophrenia. Pharmacology research & perspectives 12 (2) (2024)
Seth C Hopkins, Siriporn Toongsuwan, Taryn J Corriveau, Takao Watanabe, Yuki Tsushima, Takumi Asada, Robert Lew, Lei Shi, Vanessa Zann, Thomas J Snowden, Piet H van der Graaf, Borje Darpo, Graham E Searle, Eugenii A Rabiner, Ian Wilding, Steven T Szabo, Gerald R Galluppi, Kenneth S Koblan
Discovery and Model-Informed Drug Development of a Controlled-Release Formulation of Nonracemic Amisulpride that Reduces Plasma Exposure but Achieves Pharmacodynamic Bioequivalence in the Brain. Clinical pharmacology and therapeutics 116 (2) (2024)
Guangqing Xiao, Hironobu Tsukada, Yu-Luan Chen, Lei Shi, Seth C Hopkins, Gerald R Galluppi
Evaluation of OCT2-mediated drug-drug interactions between ulotaront and metformin in subjects with schizophrenia. Pharmacology research & perspectives 12 (2) (2024)
Seth C Hopkins, Siriporn Toongsuwan, Taryn J Corriveau, Takao Watanabe, Yuki Tsushima, Takumi Asada, Robert Lew, Lei Shi, Vanessa Zann, Thomas J Snowden, Piet H van der Graaf, Borje Darpo, Graham E Searle, Eugenii A Rabiner, Ian Wilding, Steven T Szabo, Gerald R Galluppi, Kenneth S Koblan
Discovery and Model-Informed Drug Development of a Controlled-Release Formulation of Nonracemic Amisulpride that Reduces Plasma Exposure but Achieves Pharmacodynamic Bioequivalence in the Brain. Clinical pharmacology and therapeutics (2024)
Sung M Yang, Ayan Ghoshal, Jeffrey M Hubbard, Florian Gackière, Romain Teyssié, Stuart A Neale, Seth C Hopkins, Kenneth S Koblan, Linda J Bristow, Nina Dedic
TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 49 (7) (2023)
Sung M Yang, Ayan Ghoshal, Jeffrey M Hubbard, Florian Gackière, Romain Teyssié, Stuart A Neale, Seth C Hopkins, Kenneth S Koblan, Linda J Bristow, Nina Dedic
TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2023)
Sung M Yang, Ayan Ghoshal, Jeffrey M Hubbard, Florian Gackière, Romain Teyssié, Stuart A Neale, Seth C Hopkins, Kenneth S Koblan, Linda J Bristow, Nina Dedic
TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2023)
Roberto Gomeni, Seth C Hopkins, Françoise Bressolle-Gomeni, Maurizio Fava
Interpreting clinical trial outcomes complicated by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting. Translational psychiatry 13 (1) (2023)
Roberto Gomeni, Seth C Hopkins, Françoise Bressolle-Gomeni, Maurizio Fava
Interpreting clinical trial outcomes complicated by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting. Translational psychiatry 13 (1) (2023)
Francesca Perini, Jadwiga Maria Nazimek, Shane Mckie, Liliana P Capitão, Jessica Scaife, Deepa Pal, Michael Browning, Gerard R Dawson, Hiroyuki Nishikawa, Una Campbell, Seth C Hopkins, Antony Loebel, Rebecca Elliott, Catherine J Harmer, John Francis William Deakin, Kenneth S Koblan
Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy. Schizophrenia (Heidelberg, Germany) 9 (1) (2023)
Daria Piacentino, Ajay Ogirala, Robert Lew, Gregory Loftus, MaryAlice Worden, Kenneth S Koblan, Seth C Hopkins
A Novel Method for Deriving Adverse Event Prevalence in Randomized Controlled Trials: Potential for Improved Understanding of Benefit-Risk Ratio and Application to Drug Labels. Advances in therapy (2023)
Sung M Yang, Ayan Ghoshal, Jeffrey M Hubbard, Florian Gackière, Romain Teyssié, Stuart A Neale, Seth C Hopkins, Kenneth S Koblan, Linda J Bristow, Nina Dedic
TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 49 (7) (2023)
Roberto Gomeni, Seth C Hopkins, Françoise Bressolle-Gomeni, Maurizio Fava
Interpreting clinical trial outcomes complicated by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting. Translational psychiatry 13 (1) (2023)
Sung M Yang, Ayan Ghoshal, Jeffrey M Hubbard, Florian Gackière, Romain Teyssié, Stuart A Neale, Seth C Hopkins, Kenneth S Koblan, Linda J Bristow, Nina Dedic
TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 49 (7) (2023)
Roberto Gomeni, Seth C Hopkins, Françoise Bressolle-Gomeni, Maurizio Fava
Interpreting clinical trial outcomes complicated by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting. Translational psychiatry 13 (1) (2023)
Seth C Hopkins, Ajay Ogirala, Courtney Zeni, MaryAlice Worden, Kenneth S Koblan
Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D 2 -Based Pharmacological Class Effect Query Defined by FAERS. Clinical drug investigation 42 (12) (2022)
Seth C Hopkins, Sasagu Tomioka, Ajay Ogirala, Antony Loebel, Kenneth S Koblan, Stephen R Marder
Assessment of Negative Symptoms in Clinical Trials of Acute Schizophrenia: Test of a Novel Enrichment Strategy. Schizophrenia bulletin open 3 (1) (2022)
Seth C Hopkins, Sasagu Tomioka, Ajay Ogirala, Antony Loebel, Kenneth S Koblan, Stephen R Marder
Assessment of Negative Symptoms in Clinical Trials of Acute Schizophrenia: Test of a Novel Enrichment Strategy. Schizophrenia bulletin open 3 (1) (2022)
Seth C Hopkins, Ajay Ogirala, MaryAlice Worden, Kenneth S Koblan
Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS. Clinical drug investigation 41 (12) (2021)